Meet Our Featured Speakers

For European statutory payers, obesity has moved from the margins of coverage debates to the centre of health expenditure planning. The therapeutic transformation that GLP-1 receptor agonists have delivered, with weight reductions of a magnitude previously achievable only through bariatric surgery, has confronted national health technology assessment bodies with coverage decisions on a scale their methodologies were never designed to handle. IQVIA's Outlook for Obesity in 2026, published in January 2026, characterised the current period as one of acceleration, noting that if the previous two years represented the consolidation of GLP-1 medicines into mainstream clinical practice, 2026 marks the moment coverage decisions become embedded in national health systems. The financial stakes of this shift are high against a global obesity-therapeutics market that Goldman Sachs projects will reach roughly $95 billion by 2030 and that Morgan Stanley sees peaking near $150 billion by 2035: France's Health Ministry confirmed, in announcing its reimbursement decision for Wegovy and Mounjaro in May 2026, that the full-rollout cost to public finances would be steep, and that figure reflects a deliberately restricted eligibility framework rather than open-access prescribing. Germany's Gemeinsamer Bundesausschuss has maintained the exclusion of GLP-1 therapies from statutory health insurance for the obesity indication, a position anchored in a 2004 Social Code provision that classifies lifestyle medications as outside the statutory benefit basket; no revision to that framework had been confirmed as of mid-2026.

The EU Health Technology Assessment Regulation, Regulation (EU) 2021/2282, became applicable from 12 January 2025 for new active substances in oncology and advanced therapy medicinal products, with a phased extension to orphan medicines scheduled for 2028 and to all medicines from 2030. The Joint Clinical Assessment framework now operating under this Regulation creates, for the first time, a centralised EU-level clinical assessment that national HTA agencies must take into account when making domestic reimbursement decisions. As of mid-2026, the Member State Coordination Group on Health Technology Assessment had initiated a growing number of joint clinical assessments, with the HTACG Annual Work Programme for 2026 confirming a sharp increase in future activity. Obesity therapies do not yet fall within the mandatory scope of joint clinical assessments, which currently extends only to oncology and advanced therapy medicinal products. Even so, the JCA framework will apply to all medicines from 2030 onwards, and the groundwork for aligning national evidence requirements with centralised assessment outputs is already reshaping how manufacturers approach the development of obesity therapy and market access programmes.

The Gap Between Regulatory Approval and Patient Access in European Markets

Regulatory approval by the European Medicines Agency does not translate automatically into patient access, and the gap between the two remains the defining commercial challenge for manufacturers and market access teams operating across Europe. Research presented at the International Society for Pharmacoeconomics and Outcomes Research Europe 2024 conference, and published in Value in Health, documented the reimbursement environment for GLP-1 agonists across the EU4 plus UK markets as of mid-2024, finding broadly restricted and heterogeneous access. Germany remained the greatest constraint given its statutory exclusion. The European Association for the Study of Obesity published a new pharmacotherapy framework in Nature Medicine in October 2025, setting internationally aligned clinical guidance for the use of GLP-1 therapies as a first-line treatment for obesity. For manufacturers preparing national payer submissions, this guidance provides a recognised clinical baseline, while for payers, it strengthens the coverage case and sharpens the focus on budget impact.

Private insurers, employer benefit managers, and digital health providers are, in turn, operating in the space between statutory exclusion and patient demand. Across Nordic markets, where digital health infrastructure is comparatively advanced and early adoption of new therapies has historically been higher, uptake is growing through a combination of public pathways with restricted eligibility and private market channels. Analysis published by FoodNavigator in January 2026 characterised the trajectory clearly: Europe's GLP-1 uptake would be shaped by public health budgets, prescribing pathways, and prioritisation rules rather than the consumer demand signals that drove early adoption in the United States, where the Treat and Reduce Obesity Act, a new Medicare GLP-1 bridge-access provision, and manufacturer price cuts negotiated under the TrumpRx initiative have taken the opposite policy path. Obesity Therapies Europe 2027 brings together national HTA decision-makers, statutory and private insurers, pharmaceutical manufacturers, and health economics teams to examine how coverage decisions are being made, defended, and revised as the therapeutic and fiscal backdrop continues to shift.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.